Simplify PCI! Know where and how to win with drug-coated balloon
Sponsored by B. Braun
STEMI
Stents, scaffolds and DCB
Multivessel disease
Bifurcation lesion
Symposium
B.Braun
Room 242AB
Anchorperson: Raban Jeger
Spokesperson: Simon Eccleshall
Discussants: Flavio Luciano Ribichini, Eun-Seok Shin
Watch this session if you want
- To learn more about the safety and effectiveness of the best-investigated coronary drug-coated balloons
- To learn about the strengths of drug-coated balloons in different indications, including de-novo, multivessel disease, bifurcations, CTO and diabetic patients
- To gain an understanding on how drug-coated balloon can reduce complexity in today’s PCI
- To gain confidence in using drug-coated balloon with a data-driven treatment choice
- To get an understanding how to use the hybrid approach especially for challenging lesions to improve clinical outcome
- To get the latest clinical data on the best-investigated coronary sirolimus drug-coated balloon in a real-world setting
Welcome and session objectives
Raban Jeger
Know the strengths – Evidence based treatment choice with the best-investigated Sirolimus - and Paclitaxel - drug-coated balloon
Raban Jeger
Comprehensive management of multivessel disease with drug-coated balloons
Flavio Luciano Ribichini
Simplifying bifurcation lesions using drug-coated balloons
Simon Eccleshall
Enhancing outcomes for diabetic patients with drug-coated balloons
Raban Jeger
The patient in focus – Future strategies to minimize PCI burden
Eun-Seok Shin
Discussion and audience interaction
Session evaluation and key learnings
Simon Eccleshall
